CIK 0001621227 · Non-accelerated filer<br>Smaller reporting company
Adaptimmune Therapeutics PLC
Sign in to watch- Ticker
- ADAPY
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 44 1235 430000
- Business address
- 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom
- Former names
- Adaptimmune Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 10 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-01-13 | Noble James Director | Sale | −100,000 | $4.00 | $400K | 0 |
| 2020-01-13 | Noble James Director | Sale | −200,000 | $5.00 | $1.0M | 0 |
| 2020-01-06 | Lunger John Chief Patient Supply Officer | Sale | −1,148 | $1.20 | $1K | 1,677 |
| 2020-01-06 | Bertrand William C JR Chief Operating Officer | Sale | −3,731 | $1.20 | $4K | 5,632 |
| 2020-01-06 | Rawcliffe Adrian Chief Executive Officer | Sale | −5,900 | $1.20 | $7K | 5,804 |
| 2019-09-01 | Rawcliffe Adrian CEO and CFO | Grant or award · Option to purchase Ordinary Shares | +628,872 | 628,872 | ||
| 2019-09-01 | Rawcliffe Adrian CEO and CFO | Grant or award · Option to purchase Ordinary Shares | +140,448 | 140,448 | ||
| 2019-08-06 | Amado Rafael President, R&D | Sale | −11,043 | $2.06 | $23K | 17,237 |
| 2019-08-01 | Lunger John Chief Patient Supply Officer | Grant or award · Option to purchase Ordinary Shares | +839,568 | 839,568 | ||
| 2019-08-01 | Lunger John Chief Patient Supply Officer | Grant or award · Option to purchase Ordinary Shares | +187,500 | 187,500 | ||
| 2019-07-02 | MOTT DAVID M Director | Grant or award · Option to purchase Ordinary Shares | +350,947 | 350,947 | ||
| 2019-07-02 | Behbahani Ali Director | Grant or award · Option to purchase Ordinary Shares | +234,407 | 234,407 | ||
| 2019-07-02 | Zaks Tal Zvi Director | Grant or award · Option to purchase Ordinary Shares | +124,000 | 124,000 | ||
| 2019-07-02 | Sigal Charles Elliott Director | Grant or award · Option to purchase Ordinary Shares | +234,407 | 234,407 | ||
| 2019-07-02 | Furey John Director | Grant or award · Option to purchase Ordinary Shares | +240,541 | 240,541 | ||
| 2019-07-02 | Kerr Giles Francis Bertram Director | Grant or award · Option to purchase Ordinary Shares | +124,000 | 124,000 | ||
| 2019-07-02 | Duncan Barbara Gayle Director | Grant or award · Option to purchase Ordinary Shares | +124,000 | 124,000 | ||
| 2019-07-02 | Alleva Lawrence M Director | Grant or award · Option to purchase Ordinary Shares | +271,209 | 271,209 | ||
| 2019-06-27 | Rawcliffe Adrian Chief Financial Officer | Grant or award · Option to purchase Ordinary Shares | +628,872 | 628,872 | ||
| 2019-06-27 | Rawcliffe Adrian Chief Financial Officer | Grant or award · Option to purchase Ordinary Shares | +140,448 | 140,448 |
Page 15 of 23 · 454 trades